Immungenetics is the world driver in the therapeutic targeting of ABC transporters at the blood brain barrier. A universe of 49 known ABC transporter proteins specifically regulate the exchange of substances from the Central Nervous System to the bloodstream and vice versa, safeguarding our brain. Dysfunctional transport mechanisms like the impaired clearance of toxic substances may lead to neurodegenerative processes.


Immungenetics is taking a first in class, proprietary drug for this novel mechanism of action into the clinic, which activates ABC-transporter proteins in charge of the export of toxic ABeta. The company has received the approval to start a Phase II clinical trial for Alzheimer's in Germany. The drug also serves as a trigger for the first blood-based predictive assay for (Early Onset) Alzheimer's, Dementia and Parkinson's Disease in development (companion diagnostics).


In parallel the company is elucidating its application for Huntington Disease, Lewy-Body Dementia and other proteinopathies. The current screening activities for ABC transporter modulators involve repurposed small drug molecules and new chemical entities.


Immungenetics has the most advanced mammalian-based platform to develop drugs for mitochondrial diseases. Most of the existing mitochondrial platforms are based on flies and worms which cannot fully replicate disease mechanisms of higher organisms like humans: "we see what others can't." Our approach profits from the unique MITOSANA-phenotype database which enables us to test in depth and in vivo the metabolic and mitotoxic activities of the compound before clinical development: even after acceptance, many drugs targeting mitochondria show severe side effects and often need to be retracted.


There are still over 300 known mitochondrial diseases without FDA approved medications. Whilst most of these diseases are rare, they can be profitably addressed and are key conditions to consider. In recent years Mitochondrial Dysfunctions have also increasingly been associated with chronic and age-related diseases.


Thereof we are developing solutions for over 20 diseases, including a number of inflammatory skin diseases (SLE/Lupus, Psoriasis, Pemphigus, etc), Rheumatoid Arthritis, Multiple Sclerosis, Pancreatitis, Colitis, Stress/Hypertension, Type II Diabetes, Arteriosclerosis and dietary induced Obesity. One of our most intriguing programmes deals with prolonged lifespan.


The company is currently applying for clinical trial approvals for several drug candidates and indications.